Findings of Research Misconduct, 68460-68461 [2011-28619]

Download as PDF 68460 Federal Register / Vol. 76, No. 214 / Friday, November 4, 2011 / Notices addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000. On October 18, 2011, the Secretary of HHS designated the following class of employees as an addition to the SEC: All Atomic Weapons Employees who worked at Vitro Manufacturing in Canonsburg, Pennsylvania, from January 1, 1960 through September 30, 1965, for a number of work days aggregating at least 250 work days, occurring either solely under this employment or in combination with work days within the parameters established for one or more other classes of employees in the Special Exposure Cohort. This designation will become effective on November 17, 2011, unless Congress provides otherwise prior to the effective date. After this effective date, HHS will publish a notice in the Federal Register reporting the addition of this class to the SEC or the result of any provision by Congress regarding the decision by HHS to add the class to the SEC. FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, NIOSH, 4676 Columbia Parkway, MS C– 46, Cincinnati, OH 45226, Telephone (877) 222–7570. Information requests can also be submitted by email to DCAS@CDC.GOV. John Howard, Director, National Institute for Occupational Safety and Health. [FR Doc. 2011–28574 Filed 11–3–11; 8:45 am] in any area of the Ames Laboratory at Iowa State University during the period from August 13, 1942 through December 31, 1970, for a number of work days aggregating at least 250 work days, occurring either solely under this employment or in combination with work days within the parameters established for one or more classes of employees included in the Special Exposure Cohort. This designation will become effective on November 17, 2011, unless Congress provides otherwise prior to the effective date. After this effective date, HHS will publish a notice in the Federal Register reporting the addition of this class to the SEC or the result of any provision by Congress regarding the decision by HHS to add the class to the SEC. FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, NIOSH, 4676 Columbia Parkway, MS C– 46, Cincinnati, OH 45226, Telephone (877) 222–7570. Information requests can also be submitted by Email to DCAS@CDC.GOV. John Howard, Director, National Institute for Occupational Safety and Health. [FR Doc. 2011–28575 Filed 11–3–11; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct BILLING CODE 4163–19–P Office of the Secretary, HHS. ACTION: Notice. AGENCY: DEPARTMENT OF HEALTH AND HUMAN SERVICES Designation of a Class of Employees for Addition to the Special Exposure Cohort National Institute for Occupational Safety and Health (NIOSH), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: HHS gives notice of a decision to designate a class of employees from the Ames Laboratory at Iowa State University as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000. On October 18, 2011, the Secretary of HHS designated the following class of employees as an addition to the SEC: mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: All Department of Energy (DOE) employees, its predecessor agencies, and its contractors and subcontractors who worked VerDate Mar<15>2010 17:06 Nov 03, 2011 Jkt 226001 Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Jayant Jagannathan, M.D., University of Virginia Medical Center: Based on the report of an investigation conducted by the University of Virginia (UVA) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Jayant Jagannathan, former Resident Physician at UVA Medical Center, engaged in research misconduct by plagiarizing research supported by National Institutes of Health (NIH) research and training awards and by NIH intramural research funds from the National Institute of Neurological Disorders and Stroke (NINDS), Surgical Neurosurgery Branch (NSB), and from the National Institute of Dental and Craniofacial Research (NIDCR). ORI found that the Respondent engaged in research misconduct by including, in five publications, large SUMMARY: PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 amounts of text and an illustration that he plagiarized from publications supported by the following NIH grant awards: T32 CA09677, P01 HL024136, R01 HL059157, P50 CA090270, M01 RR01346, R01 CA075979, R01 DK064169, R01 NS027544, R01 NS052406, and K08 NS002197,1 and by intramural funds from the Surgical Neurosurgery Branch, NINDS, and from NIDCR. Publications in which Respondent reported plagiarized material were: 1. Jagannathan, J., Li, J., Szerlip, N., Vortmeyer, A.O., Lonser, R.R., Oldfied, E.H., Zhuang, Z. ‘‘Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease.’’ Neurosurgery 64:4–14, 2009 (to be retracted); 2. Jagannathan, J., Prevedello, D.M., Dumont, A.S., Laws, E.R. ‘‘Cellular Signaling Molecules as Therapeutic Targets in the Treatment of Glioblastoma Multiforme.’’ Neurosurgical Focus 20(4):E8, 2006 (retracted ‘‘due to plagiarism,’’ Neurosurgical Focus 30(2):E8r, 2011); 3. Kanter, A.S., Jagannathan, J., Shaffrey, C.I., Ouellet, J.A., Mummaneni, P.V. ‘‘Inflammatory and dysplastic lesions involving the spine.’’ Neurosurgical Clinics of North America 19(1):93–109, 2008; 4. Jagannathan, J., Dumont, A.S., Prevedello, D.M., Oskouian, R.J., Lopes, B., Jane, J.A. Jr, Laws, E.R. Jr. ‘‘Genetics of pituitary adenomas: Current theories and future implications.’’ Neurosurgical Focus 19(5):E4, 2005 (retracted ‘‘due to plagiarism,’’ Neurosurgical Focus 30(2):E4r, 2011); 5. Jagannathan, J. ‘‘Role of calcium influx and modulation of local neurotransmitters as hallmarks of pediatric traumatic brain injury.’’ Biomarkers Med. 3:95–97, 2009 (retracted online 9/11/2010). Dr. Jagannathan has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of four (4) years, beginning on October 20, 2011: (1) To have his research supervised; Respondent agreed to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which his participation is proposed and prior 1 T32 CA09677, Radiation Biology Training Grant,’’ A. Kennedy, P.I. P01 HL024136, ‘‘Mechanisms of Remodeling in Chronic Airway Inflammation,’’ G. Caughey, P.I. HL059157, ‘‘Angioproteins in Airway Vascular Leak and Angiogenesis,’’ D. McDonald, P.I. P50 CA090270, ‘‘UTMDACC Cancer Center SPORE in prostate cancer,’’ C. Logothetis, P.I. M01 RR01346, ‘‘UTHSC GCRC,’’ R. Clark, P.I. R01 CA075979, ‘‘Mechanisms for Pituitary Tumorigenesis,’’ S. Melmed, P.I. R01 DK064169, ‘‘Metabolic Consequences of Sccurin Disruption,’’ S. Melmed, P.I. R01 NS027544, ‘‘Loss of Developmental Plasticity after Head Injury,’’ D.A. Hovda, P.I. R01 NS052406, ‘‘Age-dependent Ketone Metabolism after Brain Injury,’’ M.L. Prims, P.I. K08 NS002197, ‘‘NMDA Receptor Dysfunction after Traumatic Brain Injury,’’ C.C. Christopher, P.I. E:\FR\FM\04NON1.SGM 04NON1 Federal Register / Vol. 76, No. 214 / Friday, November 4, 2011 / Notices to his participation in any capacity on PHS-supported research, the institution employing him must submit a plan for supervision of his duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of his research contribution; Respondent agreed that he will not participate in any PHS-supported research after sixty (60) days from the effective date of the Agreement until a plan for supervision is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) That any institution employing him must submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; (3) To submit a letter to the journal editor for publication 3 (Neurosurgical Clinics of North America) listed above, requesting that the paper be retracted because Respondent had plagiarized portions of text reported in it; the letter must be sent to ORI for approval prior to being sent to the editor; and (4) To exclude himself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2011–28619 Filed 11–3–11; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES mstockstill on DSK4VPTVN1PROD with NOTICES Meeting of the National Toxicology Program (NTP) Board of Scientific Counselors National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health. ACTION: Meeting announcement and request for comments. AGENCY: Pursuant to Public Law 92– 463, notice is hereby given of a meeting SUMMARY: VerDate Mar<15>2010 17:06 Nov 03, 2011 Jkt 226001 of the NTP Board of Scientific Counselors (BSC). The BSC is a federally chartered, external advisory group composed of scientists from the public and private sectors that provides primary scientific oversight to the NTP and evaluates the scientific merit of the NTP’s intramural and collaborative programs. DATES: The BSC meeting will be held on December 15, 2011. The deadline for submission of written comments is December 1, 2011, and for preregistration to attend the meeting, including registering to present oral comments, is December 8, 2011. Individuals with disabilities who need accommodation to participate in this event should contact Dr. Lori White at voice telephone: (919) 541–9834 or email: whiteld@niehs.nih.gov. TTY users should contact the Federal TTY Relay Service at (800) 877–8339. Requests should be made at least 5 business days in advance of the event. ADDRESSES: The BSC meeting will be held in the Rodbell Auditorium, Rall Building at the NIEHS, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709. Public comments on all agenda topics and any other correspondence should be submitted to Dr. Lori White, Designated Federal Officer for the BSC, Office of Liaison, Policy and Review, Division of the NTP, NIEHS, P.O. Box 12233, K2–03, Research Triangle Park, NC 27709; telephone: (919) 541–9834; fax: (919) 541–0295; whiteld@niehs.nih.gov. Courier address: NIEHS, 530 Davis Drive, Room K2136, Morrisville, NC 27560. FOR FURTHER INFORMATION CONTACT: Dr. Lori White (telephone: (919) 541–9834 or whiteld@niehs.nih.gov). SUPPLEMENTARY INFORMATION: Preliminary Agenda and Meeting Materials The preliminary agenda, roster of BSC members, background materials, public comments, and any additional information, when available, will be posted on the BSC meeting Web site (https://ntp.niehs.nih.gov/go/165) or may be requested in hardcopy from the Designated Federal Officer for the BSC (see ADDRESSES above). Draft research concepts will be presented for the following three new nominations to the NTP testing program: sulfolane [CASRN 126–33–0], the phenolic benzotriazoles class, and trimethylsilyldiazomethane [CASRN 18107–18–1]. A draft concept for a workshop on permanent hair dyes will also be presented. There will be a presentation of the finalized Report on Carcinogens review process, details of PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 68461 which can be found at https:// ntp.niehs.nih.gov/go/rocprocess. Also, there will be reports on the January 2011 workshop on the role of environmental factors in development of diabetes and obesity (https:// ntp.niehs.nih.gov/go/36433) and on environmental enrichment in NTP studies. Following the meeting, summary minutes will be prepared and made available on the BSC meeting Web site. Attendance and Registration The meeting is scheduled for December 15, 2011, beginning at 8:30 a.m. EST and continuing until adjournment. This meeting is open to the public with attendance limited only by the space available. Individuals who plan to attend are encouraged to register online at the BSC meeting Web site (https://ntp.niehs.nih.gov/go/165) by December 8, 2011, to facilitate planning for the meeting. Registered attendees are encouraged to access this Web site to stay abreast of the most current information regarding the meeting. The NTP is making plans to videocast the meeting through the Internet at https:// www.niehs.nih.gov/news/video/live. Request for Comments Written comments submitted in response to this notice should be received by December 1, 2011. Comments will be posted on the BSC meeting Web site and persons submitting them will be identified by their name and affiliation and/or sponsoring organization, if applicable. Persons submitting written comments should include their name, affiliation (if applicable), phone, email, and sponsoring organization (if any) with the document. Time will be allotted during the meeting for the public to present oral comments to the BSC on the agenda topics. In addition to in-person oral comments at the meeting at the NIEHS, public comments can be presented by teleconference line. There will be 50 lines for this call; availability will be on a first-come, first-served basis. The available lines will be open from 8:30 a.m. until adjournment, although public comments will be received only during the formal public comment periods, which are indicated on the preliminary agenda. Each organization is allowed one time slot per agenda topic. At least 7 minutes will be allotted to each speaker, and if time permits, may be extended to 10 minutes at the discretion of the BSC chair. Persons wishing to present oral comments are encouraged to pre-register on the NTP meeting Web site, indicate whether they E:\FR\FM\04NON1.SGM 04NON1

Agencies

[Federal Register Volume 76, Number 214 (Friday, November 4, 2011)]
[Notices]
[Pages 68460-68461]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-28619]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Jayant Jagannathan, M.D., University of Virginia Medical Center: 
Based on the report of an investigation conducted by the University of 
Virginia (UVA) and additional analysis conducted by ORI in its 
oversight review, ORI found that Dr. Jayant Jagannathan, former 
Resident Physician at UVA Medical Center, engaged in research 
misconduct by plagiarizing research supported by National Institutes of 
Health (NIH) research and training awards and by NIH intramural 
research funds from the National Institute of Neurological Disorders 
and Stroke (NINDS), Surgical Neurosurgery Branch (NSB), and from the 
National Institute of Dental and Craniofacial Research (NIDCR).
    ORI found that the Respondent engaged in research misconduct by 
including, in five publications, large amounts of text and an 
illustration that he plagiarized from publications supported by the 
following NIH grant awards: T32 CA09677, P01 HL024136, R01 HL059157, 
P50 CA090270, M01 RR01346, R01 CA075979, R01 DK064169, R01 NS027544, 
R01 NS052406, and K08 NS002197,\1\ and by intramural funds from the 
Surgical Neurosurgery Branch, NINDS, and from NIDCR.
---------------------------------------------------------------------------

    \1\ T32 CA09677, Radiation Biology Training Grant,'' A. Kennedy, 
P.I.
    P01 HL024136, ``Mechanisms of Remodeling in Chronic Airway 
Inflammation,'' G. Caughey, P.I.
    HL059157, ``Angioproteins in Airway Vascular Leak and 
Angiogenesis,'' D. McDonald, P.I.
    P50 CA090270, ``UTMDACC Cancer Center SPORE in prostate 
cancer,'' C. Logothetis, P.I.
    M01 RR01346, ``UTHSC GCRC,'' R. Clark, P.I.
    R01 CA075979, ``Mechanisms for Pituitary Tumorigenesis,'' S. 
Melmed, P.I.
    R01 DK064169, ``Metabolic Consequences of Sccurin Disruption,'' 
S. Melmed, P.I.
    R01 NS027544, ``Loss of Developmental Plasticity after Head 
Injury,'' D.A. Hovda, P.I.
    R01 NS052406, ``Age-dependent Ketone Metabolism after Brain 
Injury,'' M.L. Prims, P.I.
    K08 NS002197, ``NMDA Receptor Dysfunction after Traumatic Brain 
Injury,'' C.C. Christopher, P.I.
---------------------------------------------------------------------------

    Publications in which Respondent reported plagiarized material 
were:

    1. Jagannathan, J., Li, J., Szerlip, N., Vortmeyer, A.O., 
Lonser, R.R., Oldfied, E.H., Zhuang, Z. ``Application and 
implementation of selective tissue microdissection and proteomic 
profiling in neurological disease.'' Neurosurgery 64:4-14, 2009 (to 
be retracted);
    2. Jagannathan, J., Prevedello, D.M., Dumont, A.S., Laws, E.R. 
``Cellular Signaling Molecules as Therapeutic Targets in the 
Treatment of Glioblastoma Multiforme.'' Neurosurgical Focus 
20(4):E8, 2006 (retracted ``due to plagiarism,'' Neurosurgical Focus 
30(2):E8r, 2011);
    3. Kanter, A.S., Jagannathan, J., Shaffrey, C.I., Ouellet, J.A., 
Mummaneni, P.V. ``Inflammatory and dysplastic lesions involving the 
spine.'' Neurosurgical Clinics of North America 19(1):93-109, 2008;
    4. Jagannathan, J., Dumont, A.S., Prevedello, D.M., Oskouian, 
R.J., Lopes, B., Jane, J.A. Jr, Laws, E.R. Jr. ``Genetics of 
pituitary adenomas: Current theories and future implications.'' 
Neurosurgical Focus 19(5):E4, 2005 (retracted ``due to plagiarism,'' 
Neurosurgical Focus 30(2):E4r, 2011);
    5. Jagannathan, J. ``Role of calcium influx and modulation of 
local neurotransmitters as hallmarks of pediatric traumatic brain 
injury.'' Biomarkers Med. 3:95-97, 2009 (retracted online 9/11/
2010).

    Dr. Jagannathan has entered into a Voluntary Settlement Agreement 
(Agreement) and has voluntarily agreed for a period of four (4) years, 
beginning on October 20, 2011:
    (1) To have his research supervised; Respondent agreed to ensure 
that prior to the submission of an application for U.S. Public Health 
Service (PHS) support for a research project on which his participation 
is proposed and prior

[[Page 68461]]

to his participation in any capacity on PHS-supported research, the 
institution employing him must submit a plan for supervision of his 
duties to ORI for approval; the plan for supervision must be designed 
to ensure the scientific integrity of his research contribution; 
Respondent agreed that he will not participate in any PHS-supported 
research after sixty (60) days from the effective date of the Agreement 
until a plan for supervision is submitted to and approved by ORI; 
Respondent agreed to maintain responsibility for compliance with the 
agreed upon supervision plan;
    (2) That any institution employing him must submit, in conjunction 
with each application for PHS funds, or report, manuscript, or abstract 
involving PHS-supported research in which Respondent is involved, a 
certification to ORI that the data provided by Respondent are based on 
actual experiments or are otherwise legitimately derived and that the 
data, procedures, and methodology are accurately reported in the 
application, report, manuscript, or abstract;
    (3) To submit a letter to the journal editor for publication 3 
(Neurosurgical Clinics of North America) listed above, requesting that 
the paper be retracted because Respondent had plagiarized portions of 
text reported in it; the letter must be sent to ORI for approval prior 
to being sent to the editor; and
    (4) To exclude himself from serving in any advisory capacity to PHS 
including, but not limited to, service on any PHS advisory committee, 
board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. 2011-28619 Filed 11-3-11; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.